After just over 6 months from beginning of the project, the TIGER consortium met in Mechelen (Belgium) on 13th and 14th September to review the project activities already undertaken and to set the basis for further work. On the agenda over the two days was the overall technical management of the project, ongoing tasks and upcoming work.
All partners presented their main results and established discussions to ensure collaborative work and planning for the Phase I clinical study in HPV+ cancers aiming to start in early 2022 and development of innovative biomedical diagnostic tools that will be undertaken by the TIGER project.
Discussion also focussed on the dissemination strategy to guarantee the appropriate communication of the project and make sure all audiences appreciate the objectives of the project.
The meeting provided partners with a clear vision of the directions to be taken with the research and tasks at hand over the coming months.